Ligand Pharmaceuticals Incorporated

    Jurisdiction
    United States
    LEI
    5493008K7TB0IKP37H79
    ISIN
    US53220K5048 (LGND)
    Sectors
    1. Healthcare
    2. Medical - Pharmaceuticals

    Scores

    InsiderPie Expert Score
    53 / 100
    Better than peer group:
    49 / 100
    Fair value (Benjamin Graham formula)
    €53.93 193.0% overvalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Read full profile

    Fundamentals

    Net revenue
    €160.00M
    Gross margin
    44.7%
    EBIT
    -€29.23M
    EBIT margin
    -18.3%
    Net income
    -€53.83M
    Net margin
    -33.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €209.63M +31.0% €74.38M -238.2%
    €257.09M +22.6% €101.33M +36.2%
    €292.13M +13.6% €109.63M +8.2%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.12
    Ex date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    KOZARICH JOHN W N/A -467 $162.26 -$75.78K
    KOZARICH JOHN W N/A -467 $131.88 -$61.59K

    Earnings Calls

    Earnings Calls

    Latest earnings call: May 7, 2024 (Q1 2024)

    Add to watchlist

    Notifications